INDV Overview

Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.

Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is43.75 USD with a low forecast of 36.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Indivior Pharmaceuticals, Inc revenue for the last quarter amounts to 358.00M USD, increased 19.73

Indivior Pharmaceuticals, Inc. EPS for the last quarter amounts to 0.78 USD, increased 387.50

Indivior Pharmaceuticals, Inc (INDV) has 827 emplpoyees as of April 30 2026.

Today INDV has the market capitalization of 4.20B USD.